Clinical trials: Chemoradiation
Oral Mucositis, Quality of Life
Retrospective Observational Study of Oral Complications and Quality of Life in Head and Neck Cancer Patients Treated With Radiotherapy or Chemoradiotherapy.
Head and Neck cancer patients receiving radiation therapy (with or without chemotherapy) suffer several oral complications, such as oral mucositis, which impairs quality of life of patients during radiotherapy and in the…
- Conditions
- Oral Mucositis, Quality of Life, Mucositis, Pain
- Trial name
- NCT07739771
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Mucosa Innovations, S.L.
Newly Diagnosed Glioblastoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
This is a single-arm, open-label phase II clinical trial in which approximately 55 patients with newly diagnosed glioblastoma (GBM) will be enrolled with the intent to receive an autologous dendritic cell vaccine consisting of…
- Trial name
- NCT03400917
- Testing
- AV-GBM-1
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Aivita Biomedical, Inc.
Carcinoma, Non-Small-Cell Lung
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response…
- Trial name
- CONVERGE (NCT06667908)
- Testing
- JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT)
- Where
- 44 sites in United States, Australia and 8 more
- Volunteers
- 130 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Lung Neoplasms
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
Primary Objective: To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxel/cisplatin in…
- Trial name
- NCT00174772
- Testing
- docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy, docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin
- Where
- 8 sites in Belgium, Finland and 6 more
- Volunteers
- 72 people
- Sponsor
- Sanofi
Head and Neck Cancer
Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT
Primary Objective: To evaluate the population prevalence of critical body weight loss ( more than 5% from baseline) in patients with Head and Neck cancer.
- Trial name
- NCT02980653
- Testing
- Megestrol acetate (MA) 400 mg/day
- Where
- Taiwan
- Volunteers
- 105 people
- Sponsor
- TTY Biopharm
Neoadjuvant Therapy in Rectal Cancer
Preoperative Radiotherapy and E7046 in Rectum Cancer
This is a multicenter, open-label, Phase 1b study in participants with locally advanced rectum cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by magnetic resonance imaging…
- Trial name
- PRAER 1 (NCT03152370)
- Testing
- E7046, Long Course Chemoradiotherapy (LCRT), Short Course Radiotherapy (SCRT)
- Where
- 5 sites in United States, Poland and 1 more
- Volunteers
- 29 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Neoplasm Malignant, Gastric Neoplasms
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
The goal of this study is to assess the safety of pembrolizumab with chemotherapy or chemoradiotherapy in participants in India for: Advanced gastric or gastroesophageal junction [GEJ] cancer that is (human epidermal growth…
- Conditions
- Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma
- Trial name
- NCT07801027
- Testing
- Pembrolizumab, Cisplatin, 5-Fluorouracil
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
Primary : To determine the safety profile of each treatment group. Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.
- Trial name
- NCT00271323
- Testing
- docetaxel and cisplatin, radiotherapy
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Sanofi
Esophagitis
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 (avasopasem manganese) administered intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving chemoradiotherapy for…
- Trial name
- NCT04225026
- Testing
- GC4419 (avasopasem manganese)
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Galera Therapeutics, Inc.
HepatoCellular Carcinoma, Portal Vein Tumor Thrombosis
Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
This is a phase I/II dose-escalation study of lipotecan based concurrent chemoradiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
- Trial name
- NCT03035006
- Testing
- Lipotecan
- Where
- 4 sites in Taiwan
- Volunteers
- 1 people
- Sponsor
- Taiwan Liposome Company
Head and Neck Cancer
A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer
To investigate the efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer following administration of rebamipide and to determine the optimal dose of rebamipide.
- Trial name
- NCT02085460
- Testing
- 2% Rebamipide liquid, 4% Rebamipide liquid
- Where
- 5 sites in Japan
- Volunteers
- 94 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Small-cell Lung Cancer
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease…
- Trial name
- NCT06789796
- Testing
- Iparomlimab and Tuvonralimab (QL1706), QL1604
- Volunteers
- 636 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Rectal Cancer
Tecemotide (L-BLP25) in Rectal Cancer
The objective of this mechanistic study is to determine the impact of tecemotide (L-BLP25) administration on the mucinous glycoprotein 1 - (MUC1) specific immune response in subjects with newly diagnosed rectal cancer who are…
- Trial name
- SPRINT (NCT01507103)
- Testing
- Tecemotide (L-BLP25), cyclophosphamide (CPA), Chemoradiotherapy
- Where
- Netherlands
- Volunteers
- 124 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Radiation Pneumonitis, Lung Cancer
Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients
The purpose of this clinical trial is to evaluate the safety when HL301 is administered to unresectable non-small cell lung cancer patients who receive chemoradiotherapy with Paclitaxel and Carboplatin and to search for a…
- Trial name
- NCT04632342
- Testing
- HL301 tablet 300mg
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Small Cell Lung Cancer
INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
This is a clinical study on the use of iNK cells for the treatment of small cell lung cancer.
- Trial name
- iNK-SCLC (NCT06747832)
- Testing
- iNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD
Cancer-related Fatigue, Survival
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
The primary objective of this study is to evaluate the efficacy of PG2 concurrent with concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced esophageal cancer patients who are under preoperative…
- Conditions
- Cancer-related Fatigue, Survival, Tumor, Esophageal
- Trial name
- NCT03611712
- Testing
- Astragalus Polysaccharides 500 mg
- Where
- 4 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- PhytoHealth Corporation
Carcinoma, Non-Small-Cell Lung
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy
To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in…
- Trial name
- NCT03643484
- Where
- 37 sites in Japan
- Volunteers
- 634 people
- Sponsor
- AstraZeneca
Rectal Neoplasms
Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer
Primary: To assess complete pathological response rate of both strategies. Secondary: Safety profile To assess downstaging rate of both strategies.
- Trial name
- NCT00421824
- Testing
- Oxaliplatin, capecitabine
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Sanofi
Head and Neck Cancer, Squamous Cell Carcinoma
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed.
- Trial name
- NCT00500760
- Testing
- Cisplatin, Standard Fractionation Radiotherapy, Panitumumab
- Volunteers
- 153 people
- Sponsor
- Amgen
Locally Advanced Resectable Rectal Cancer
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.
- Trial name
- NCT07454720
- Testing
- Adebrelimab in combination with SHR-8068 and chemotherapy, Adebrelimab combined with chemotherapy, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 165 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.